r-n-jРоссийский неврологический журналRussian neurological journal2658-79472686-7192МИА10.30629/2658-7947-2023-28-2-5-14r-n-j-408Research ArticleОБЗОРLITERATURE REVIEWМиастения гравис: особенности эпидемиологии, патогенеза, лечения и взаимосвязь с тимомамиMyastenia gravis: features of epidemiology, pathogenesis, treatment and relation to thymomashttps://orcid.org/0000-0002-7616-3899ГарифуллинА. И.GarifullinA. I.

Гарифуллин Айрат Ильдарович

Москва

Garifullin Airat I.

Moscow

sagidullin12@bk.ruhttps://orcid.org/0000-0002-4763-9691СултановаЭ. И.SultanovaE. I.

Уфа

Ufa

sultanovaev@bk.ruhttps://orcid.org/0000-0003-2760-7454АсфандияроваИ. В.AsfandiyarovaI. V.

Уфа

Ufa

asfandiyfokin@mail.ruhttps://orcid.org/0000-0001-8122-4417ХусаиноваА. Б.KhusainovaA. B.

Уфа

Ufa

xusainova_aygul@inbox.ruhttps://orcid.org/0000-0003-0096-8380ГордееваМ. Э.GordeevaM. E.

Уфа

Ufa

xusainova_aygul@inbox.ruhttps://orcid.org/0000-0003-3871-9283ШакироваА. Р.ShakirovaA. R.

Уфа

Ufa

shakirovaarina1@gmail.comhttps://orcid.org/0000-0002-5369-9789КорнееваА. А.KorneevaA. A.

Уфа

Ufa

Tonya082012@gmail.comhttps://orcid.org/0000-0002-6509-412XТукаевА. Ф.TukaevA. F.

Уфа

Ufa

tukaefartur@gmail.comhttps://orcid.org/0000-0002-0494-2674ЕфремоваД. Н.EfremovaD. N.

Уфа

Ufa

DaryaX.Efremova@yandex.ruhttps://orcid.org/0000-0002-0766-9490СиницинаА. С.SinitsinaA. S.

Уфа

Ufa

alinassss@yandex.ruhttps://orcid.org/0000-0003-4963-5114СобянинаЕ. О.SobyaninaE. O.

Уфа

Ufa

ekaterinasobanina5@gmail.comhttps://orcid.org/0000-0002-9892-5970УсмановаА. Р.UsmanovaA. R.

Уфа

Ufa

airitta.usmanova@yandex.ruhttps://orcid.org/0000-0002-7127-6325ИхсановаЭ. И.IkhsanovaE. I.

Уфа

Ufa

elmira.ihsanova2015@yandex.ruМНИОИ им. П.А. Герцена — филиал ФГБУ «НМИЦ радиологии»РоссияP. Hertsen Moscow Oncology Research InstituteRussian FederationБашкирский государственный медицинский университетРоссияBashkir State Medical UniversityRussian Federation202318052023282514Copyright © Гарифуллин А.И., Султанова Э.И., Асфандиярова И.В., Хусаинова А.Б., Гордеева М.Э., Шакирова А.Р., Корнеева А.А., Тукаев А.Ф., Ефремова Д.Н., Синицина А.С., Собянина Е.О., Усманова А.Р., Ихсанова Э.И., 20232023Гарифуллин А.И., Султанова Э.И., Асфандиярова И.В., Хусаинова А.Б., Гордеева М.Э., Шакирова А.Р., Корнеева А.А., Тукаев А.Ф., Ефремова Д.Н., Синицина А.С., Собянина Е.О., Усманова А.Р., Ихсанова Э.И.Garifullin A.I., Sultanova E.I., Asfandiyarova I.V., Khusainova A.B., Gordeeva M.E., Shakirova A.R., Korneeva A.A., Tukaev A.F., Efremova D.N., Sinitsina A.S., Sobyanina E.O., Usmanova A.R., Ikhsanova E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.r-n-j.com/jour/article/view/408

Проведена систематизация последних научных данных по патогенезу, генетическим особенностям, методам лечения миастении, а также взаимосвязи между миастенией и другими заболеваниями. Для поиска опубликованных исследований использовались следующие базы данных: Pubmed, Web of Science, EBSCOhost и Scopus. Поиск производился во временном интервале с даты создания соответствующей базы данных до октября 2022 года. Использовались поисковые термины «myasthenia gravis», «myasthenia treatment», «myasthenia epidemiological features», «“myasthenia and thymoma” myasthenia pathogenesis». Обозначены основные исследования, касающиеся эпидемиологии миастении, приведены ключевые клинические формы и их патогенетические характеристики, связь миастении с тимомой, основные методы лечения.

Мyasthenia gravis is a common disease, for adequate treatment of which early detection, knowledge of its clinical manifestations and possible methods of therapy is required. This review provides up-to-date information regarding the issues of myasthenia gravis. The aim of the paper: to systematize the latest scientific data on the pathogenesis, genetic characteristics, methods of treatment of myasthenia gravis, as well as to identify the relationship between myasthenia gravis and other diseases. The following databases were used to search for published studies: Pubmed, Web of Science, EBSCOhost and Scopus. The search was carried out in the time period from the date of establishment of the corresponding database until October 2022. Following search terms were used: “myasthenia gravis”, “myasthenia treatment”, “myasthenia epidemiological features”, “myasthenia and thymoma “myasthenia pathogenesis””. Тhe main studies on the epidemiology of myasthenia gravis are indicated, the key clinical forms and their pathogenetic characteristics, the relationship between myasthenia gravis and thymoma, and the main methods of treatment are also given.

миастения гравистимомаэпидемиологияаутоантителаацетилхолиновые рецепторыклинические особенностиmyasthenia gravisthymomaepidemiologyautoantibodiesacetylcholine receptorsclinical featuresReferencesDresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med. 2021;10(11):2235. https://doi.org/10.3390/jcm10112235Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. J Clin Med. 2021;10(11):2235. https://doi.org/10.3390/jcm10112235Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–2854. https://doi.org/10.1172/JCI29894Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J Clin Invest. 2006;116(11):2843–2854. https://doi.org/10.1172/JCI29894Avidan N, Le Panse R, Berrih-Aknin S, Miller A. Genetic basis of myasthenia gravis — a comprehensive review. J Autoimmun. 2014;52:146–153. https://doi.org/10.1016/j.jaut.2013.12.001Avidan N, Le Panse R, Berrih-Aknin S, Miller A. Genetic basis of myasthenia gravis — a comprehensive review. J Autoimmun. 2014;52:146–153. https://doi.org/10.1016/j.jaut.2013.12.001Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7–16. https://doi.org/10.25122/jml-2020-0145Bubuioc AM, Kudebayeva A, Turuspekova S, Lisnic V, Leone MA. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7–16. https://doi.org/10.25122/jml-2020-0145Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classifi cation of autoimmune myasthenia gravis. J Autoimmun. 2014;48–49:143–148. https://doi.org/10.1016/j.jaut.2014.01.003Berrih-Aknin S, Frenkian-Cuvelier M, Eymard B. Diagnostic and clinical classifi cation of autoimmune myasthenia gravis. J Autoimmun. 2014;48–49:143–148. https://doi.org/10.1016/j.jaut.2014.01.003Cleanthous S, Mork AC, Regnault A, Cano S, Kaminski HJ, Morel T. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):457. https://doi.org/10.1186/s13023-021-02064-0Cleanthous S, Mork AC, Regnault A, Cano S, Kaminski HJ, Morel T. Development of the Myasthenia Gravis (MG) Symptoms PRO: a case study of a patient-centred outcome measure in rare disease. Orphanet J Rare Dis. 2021;16(1):457. https://doi.org/10.1186/s13023-021-02064-0Isbister CM, Mackenzie PJ, Anderson D, Wade NK, Oger J. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult Scler. 2003;9(6):550–553. https://doi.org/10.1191/1352458503ms964oaIsbister CM, Mackenzie PJ, Anderson D, Wade NK, Oger J. Co-occurrence of multiple sclerosis and myasthenia gravis in British Columbia. Mult Scler. 2003;9(6):550–553. https://doi.org/10.1191/1352458503ms964oaDeymeer F. History of Myasthenia Gravis Revisited. Noro Psikiyatr Ars. 2020;58(2):154–162. https://doi.org/10.29399/npa.27315Deymeer F. History of Myasthenia Gravis Revisited. Noro Psikiyatr Ars. 2020;58(2):154–162. https://doi.org/10.29399/npa.27315Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–149. https://doi.org/10.1002/mus.20950Grob D, Brunner N, Namba T, Pagala M. Lifetime course of myasthenia gravis. Muscle Nerve. 2008;37(2):141–149. https://doi.org/10.1002/mus.20950Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classifi cation, Clinical Presentation, Natural History, and Epidemiology. Neurol Clin. 2018;36(2):253–260. https://doi.org/10.1016/j.ncl.2018.01.002Hehir MK, Silvestri NJ. Generalized Myasthenia Gravis: Classifi cation, Clinical Presentation, Natural History, and Epidemiology. Neurol Clin. 2018;36(2):253–260. https://doi.org/10.1016/j.ncl.2018.01.002Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. https://doi.org/10.1186/1471-2377-10-46Carr AS, Cardwell CR, McCarron PO, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46. https://doi.org/10.1186/1471-2377-10-46Santos E, Coutinho E, Moreira I, Silva AM, Lopes D, Costa H et al. Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases. Muscle Nerve. 2016;54(3):413–421. https://doi.org/10.1002/mus.25068Santos E, Coutinho E, Moreira I, Silva AM, Lopes D, Costa H et al. Epidemiology of myasthenia gravis in Northern Portugal: Frequency estimates and clinical epidemiological distribution of cases. Muscle Nerve. 2016;54(3):413–421. https://doi.org/10.1002/mus.25068Хатхе ЮА, Заболотских НВ, Терпелец СА. Эпидемиологические и популяционные аспекты миастении в Краснодарском крае. Нервно-мышечные болезни. 2018;8(1):28–33. https://doi.org/10.17650/2222-8721-2018-8-1-28-33Hatкhe YA, Zabolotskih NV, Terpelec SA. Epidemiological and population aspects of myasthenia gravis in the Krasnodar district. Neuromuscular diseases (Nervno-myshechnye bolezni). 2018;8(1):28–33. (In Russ.). https://doi.org/10.17650/2222-8721-2018-8-1-28-33Ишмухаметова АТ, Мусин РГ, Хидиятова ИМ, Магжанов РВ. Эпидемиологическое исследование миастении гравис в Республике Башкортостан. Неврологический журнал. 2006;11(6):16–21. URL: https://www.elibrary.ru/item.asp?id=9313415Ishmuhametova AT, Musin RG, Hidiyatova IM, Magzhanov RV. Epidemiological study of myasthenia gravis in the Republic of Bashkortostan. Neurological Journal (Nevrologicheskiy Zhurnal). 2006;11(6):16–21. (In Russ.). URL: https://www.elibrary.ru/item.asp?id=9313415Романова ТВ. Эпидемиологическое исследование миастении гравис в Самарской области. Саратовский научно-медицинский журнал. 2012;8(1):091–095. URL: https://ssmj.ru/2012/1/091Romanova TV. Epidemiological study of myasthenia gravis in the Samara region. Saratov Scientific Medical Journal (Saratovskij nauchno-medicinskij zhurnal). 2012;8(1):091–095. (In Russ.). URL: https://ssmj.ru/2012/1/091Заславский ЛГ, Хуршилов АБ. Основные клинико-эпидемиологические показатели миастении в Ленинградской области. Ученые записки Санкт-Петербургского государственного медицинского университета имени академика И.П. Павлова. 2015;22(4):40–43. https://doi.org/10.24884/1607-4181-2015-22-4-40-43Zaslavsky LG, Hurshilov AB. Main clinic and epidemiological factors of myasthenia in Leningrad region. The Scientifi c Notes of the Pavlov University (Uchenye zapiski Sankt-Peterburgskogo gosudarstvennogo medicinskogo universiteta imeni akademika I.P. Pavlova). 2015;22(4):40–43. (In Russ.). https://doi.org/10.24884/1607-4181-2015-22-4-40-43Koneczny I, Herbst R. Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Cells. 2019;8(7):671. https://doi.org/10.3390/cells8070671Koneczny I, Herbst R. Myasthenia Gravis: Pathogenic Effects of Autoantibodies on Neuromuscular Architecture. Cells. 2019;8(7):671. https://doi.org/10.3390/cells8070671Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366–374. https://doi.org/10.1111/cei.13546Uzawa A, Kuwabara S, Suzuki S, Imai T, Murai H, Ozawa Y et al. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis. Clin Exp Immunol. 2021;203(3):366–374. https://doi.org/10.1111/cei.13546Lee JY, Stathopoulos P, Gupta S, Bannock JM, Barohn RJ, Cotzomi E et al. Compromised fi delity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Ann Clin Transl Neurol. 2016;3(6):443–454. https://doi.org/10.1002/acn3.311Lee JY, Stathopoulos P, Gupta S, Bannock JM, Barohn RJ, Cotzomi E et al. Compromised fi delity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis. Ann Clin Transl Neurol. 2016;3(6):443–454. https://doi.org/10.1002/acn3.311Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR et al. Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. J Immunol. 2017;198(4):1460–1473. https://doi.org/10.4049/jimmunol.1601415Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR et al. Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. J Immunol. 2017;198(4):1460–1473. https://doi.org/10.4049/jimmunol.1601415Takaba H, Takayanagi H. The Mechanisms of T Cell Selection in the Thymus. Trends Immunol. 2017;38(11):805–816. https://doi.org/10.1016/j.it.2017.07.010Takaba H, Takayanagi H. The Mechanisms of T Cell Selection in the Thymus. Trends Immunol. 2017;38(11):805–816. https://doi.org/10.1016/j.it.2017.07.010Poëa-Guyon S, Christadoss P, Le Panse R, Guyon T, De Baets M, Wakkach A et al. Eff ects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol. 2005;174(10):5941–5949. https://doi.org/10.4049/jimmunol.174.10.5941Poëa-Guyon S, Christadoss P, Le Panse R, Guyon T, De Baets M, Wakkach A et al. Eff ects of cytokines on acetylcholine receptor expression: implications for myasthenia gravis. J Immunol. 2005;174(10):5941–5949. https://doi.org/10.4049/jimmunol.174.10.5941Dragin N, Bismuth J, Cizeron-Clairac G, Biferi MG, Berthault C, Serraf A et al. Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases. J Clin Invest. 2016;126(4):1525–1537. https://doi.org/10.1172/JCI81894Dragin N, Bismuth J, Cizeron-Clairac G, Biferi MG, Berthault C, Serraf A et al. Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases. J Clin Invest. 2016;126(4):1525–1537. https://doi.org/10.1172/JCI81894Truffault F, de Montpreville V, Eymard B, Sharshar T, Le Panse R, Berrih-Aknin S. Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review. Clin Rev Allergy Immunol. 2017;52(1):108–124. https://doi.org/10.1007/s12016-016-8558-3Truff ault F, de Montpreville V, Eymard B, Sharshar T, Le Panse R, Berrih-Aknin S. Thymic Germinal Centers and Corticosteroids in Myasthenia Gravis: an Immunopathological Study in 1035 Cases and a Critical Review. Clin Rev Allergy Immunol. 2017;52(1):108–124. https://doi.org/10.1007/s12016-016-8558-3Vrolix K, Fraussen J, Losen M, Stevens J, Lazaridis K, Molenaar PC et al. Clonal heterogeneity of thymic B cells from earlyonset myasthenia gravis patients with antibodies against the acetylcholine receptor. J Autoimmun. 2014;52:101–112. https://doi.org/10.1016/j.jaut.2013.12.008Vrolix K, Fraussen J, Losen M, Stevens J, Lazaridis K, Molenaar PC et al. Clonal heterogeneity of thymic B cells from earlyonset myasthenia gravis patients with antibodies against the acetylcholine receptor. J Autoimmun. 2014;52:101–112. https://doi.org/10.1016/j.jaut.2013.12.008Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular Helper T Cells. Annu Rev Immunol. 2016;34:335–368. https://doi.org/10.1146/annurev-immunol-041015-055605Vinuesa CG, Linterman MA, Yu D, MacLennan IC. Follicular Helper T Cells. Annu Rev Immunol. 2016;34:335–368. https://doi.org/10.1146/annurev-immunol-041015-055605Gradolatto A, Nazzal D, Truff ault F, Bismuth J, Fadel E, Foti M, Berrih-Aknin S. Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-α. J Autoimmun. 2014;52:53–63. https://doi.org/10.1016/j.jaut.2013.12.015Gradolatto A, Nazzal D, Truff ault F, Bismuth J, Fadel E, Foti M, Berrih-Aknin S. Both Treg cells and Tconv cells are defective in the Myasthenia gravis thymus: roles of IL-17 and TNF-α. J Autoimmun. 2014;52:53–63. https://doi.org/10.1016/j.jaut.2013.12.015Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89(1):73–120. https://doi.org/10.1152/physrev.00015.2008Albuquerque EX, Pereira EF, Alkondon M, Rogers SW. Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev. 2009;89(1):73–120. https://doi.org/10.1152/physrev.00015.2008Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev. 1998;163:89–120. https://doi.org/10.1111/j.1600-065x.1998.tb01190.xTzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev. 1998;163:89–120. https://doi.org/10.1111/j.1600-065x.1998.tb01190.xKordas G, Lagoumintzis G, Sideris S, Poulas K, Tzartos SJ. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients [published correction appears in PLoS One. 2015;10(1):e0117673] [published correction appears in PLoS One. 2015;10(3):e0120947]. PLoS One. 2014;9(9):e108327. Published 2014 Sep 26. https://doi.org/10.1371/journal.pone.0108327Kordas G, Lagoumintzis G, Sideris S, Poulas K, Tzartos SJ. Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients [published correction appears in PLoS One. 2015;10(1):e0117673] [published correction appears in PLoS One. 2015;10(3):e0120947]. PLoS One. 2014;9(9):e108327. Published 2014 Sep 26. https://doi.org/10.1371/journal.pone.0108327Fostieri E, Beeson D, Tzartos SJ. The conformation of the main immunogenic region on the alpha-subunit of muscle acetylcholine receptor is affected by neighboring receptor subunits. FEBS Lett. 2000;481(2):127–130. https://doi.org/10.1016/s0014-5793(00)01980-3Fostieri E, Beeson D, Tzartos SJ. The conformation of the main immunogenic region on the alpha-subunit of muscle acetylcholine receptor is affected by neighboring receptor subunits. FEBS Lett. 2000;481(2):127–130. https://doi.org/10.1016/s0014-5793(00)01980-3Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146(2):294–302. https://doi.org/10.1111/j.1365-2249.2006.03205.xMorgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146(2):294–302. https://doi.org/10.1111/j.1365-2249.2006.03205.xRødgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987;67(1):82–88. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1542559/Rødgaard A, Nielsen FC, Djurup R, Somnier F, Gammeltoft S. Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3. Clin Exp Immunol. 1987;67(1):82–88. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1542559/Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146(2):294–302. https://doi.org/10.1111/j.1365-2249.2006.03205.xMorgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146(2):294–302. https://doi.org/10.1111/j.1365-2249.2006.03205.xKim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 2008;135(2):334–342. https://doi.org/10.1016/j.cell.2008.10.002Kim N, Stiegler AL, Cameron TO, Hallock PT, Gomez AM, Huang JH, et al. Lrp4 is a receptor for Agrin and forms a complex with MuSK. Cell. 2008;135(2):334–342. https://doi.org/10.1016/j.cell.2008.10.002Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40. https://doi.org/10.1002/mus.22006Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44(1):36–40. https://doi.org/10.1002/mus.22006Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008;63(6):782–789. https://doi.org/10.1002/ana.21371Cole RN, Reddel SW, Gervásio OL, Phillips WD. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008;63(6):782–789. https://doi.org/10.1002/ana.21371Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW et al. Clinical fl uctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol. 2008;195(1–2):151–156. https://doi.org/10.1016/j.jneuroim.2008.01.013Niks EH, van Leeuwen Y, Leite MI, Dekker FW, Wintzen AR, Wirtz PW et al. Clinical fl uctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1. J Neuroimmunol. 2008;195(1–2):151–156. https://doi.org/10.1016/j.jneuroim.2008.01.013Poulas K, Koutsouraki E, Kordas G, Kokla A, Tzartos SJ. Anti- MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol. 2012;250(1–2):94–98. https://doi.org/10.1016/j.jneuroim.2012.05.011Poulas K, Koutsouraki E, Kordas G, Kokla A, Tzartos SJ. Anti- MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol. 2012;250(1–2):94–98. https://doi.org/10.1016/j.jneuroim.2012.05.011Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classifi cation and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–1036. https://doi.org/10.1016/S1474-4422(15)00145-3Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classifi cation and therapeutic strategies. Lancet Neurol. 2015;14(10):1023–1036. https://doi.org/10.1016/S1474-4422(15)00145-3Cortés-Vicente E, Gallardo E, Martínez MÁ, Díaz-Manera J, Querol L, Rojas-García R, Illa I. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurol. 2016;73(9):1099–1104. https://doi.org/10.1001/jamaneurol.2016.2032Cortés-Vicente E, Gallardo E, Martínez MÁ, Díaz-Manera J, Querol L, Rojas-García R, Illa I. Clinical Characteristics of Patients With Double-Seronegative Myasthenia Gravis and Antibodies to Cortactin. JAMA Neurol. 2016;73(9):1099–1104. https://doi.org/10.1001/jamaneurol.2016.2032Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418–422. https://doi.org/10.1002/ana.22312Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann Neurol. 2011;69(2):418–422. https://doi.org/10.1002/ana.22312Rivner MH, Quarles BM, Pan JX, Yu Z, Howard JF Jr, Corse A et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle Nerve. 2020;62(3):333–343. https://doi.org/10.1002/mus.26985Rivner MH, Quarles BM, Pan JX, Yu Z, Howard JF Jr, Corse A et al. Clinical features of LRP4/agrin-antibody-positive myasthenia gravis: A multicenter study. Muscle Nerve. 2020;62(3):333–343. https://doi.org/10.1002/mus.26985Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69(4):445–451. https://doi.org/10.1001/archneurol.2011.2393Zhang B, Tzartos JS, Belimezi M, Ragheb S, Bealmear B, Lewis RA et al. Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol. 2012;69(4):445–451. https://doi.org/10.1001/archneurol.2011.2393Zagoriti Z, Kambouris ME, Patrinos GP, Tzartos SJ, Poulas K. Recent advances in genetic predisposition of myasthenia gravis. Biomed Res Int. 2013;2013:404053. https://doi.org/10.1155/2013/404053Zagoriti Z, Kambouris ME, Patrinos GP, Tzartos SJ, Poulas K. Recent advances in genetic predisposition of myasthenia gravis. Biomed Res Int. 2013;2013:404053. https://doi.org/10.1155/2013/404053Pirskanen R. Genetic aspects in myasthenia gravis. A family study of 264 Finnish patients. Acta Neurol Scand. 1977;56(5):365–388 URL: https://pubmed.ncbi.nlm.nih.gov/596124/Pirskanen R. Genetic aspects in myasthenia gravis. A family study of 264 Finnish patients. Acta Neurol Scand. 1977;56(5):365–388 URL: https://pubmed.ncbi.nlm.nih.gov/596124/Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72(4):396–404. https://doi.org/10.1001/jamaneurol.2014.4103Renton AE, Pliner HA, Provenzano C, Evoli A, Ricciardi R, Nalls MA et al. A genome-wide association study of myasthenia gravis. JAMA Neurol. 2015;72(4):396–404. https://doi.org/10.1001/jamaneurol.2014.4103Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CI. Diff erent HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics. 1990;31(5–6):285–290. https://doi.org/10.1007/BF02115001Carlsson B, Wallin J, Pirskanen R, Matell G, Smith CI. Diff erent HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics. 1990;31(5–6):285–290. https://doi.org/10.1007/BF02115001Horton R, Gibson R, Coggill P, Miretti M, Allcock RJ, Almeida J et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics. 2008;60(1):1–18. https://doi.org/10.1007/s00251-007-0262-2Horton R, Gibson R, Coggill P, Miretti M, Allcock RJ, Almeida J et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics. 2008;60(1):1–18. https://doi.org/10.1007/s00251-007-0262-2From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612–632. https://doi.org/10.1177/1747493018778713From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612–632. https://doi.org/10.1177/1747493018778713Fernández-Mestre MT, Vargas V, Montagnani S, Cotúa M, Ogando V, Layrisse Z. HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis. Hum Immunol. 2004;65(1):54–59. https://doi.org/10.1016/j.humimm.2003.10.003Fernández-Mestre MT, Vargas V, Montagnani S, Cotúa M, Ogando V, Layrisse Z. HLA class II and class I polymorphism in Venezuelan patients with myasthenia gravis. Hum Immunol. 2004;65(1):54–59. https://doi.org/10.1016/j.humimm.2003.10.003Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52(10):1121–1127. https://doi.org/10.1136/jnnp.52.10.1121Oosterhuis HJ. The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989;52(10):1121–1127. https://doi.org/10.1136/jnnp.52.10.1121Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273(1–2):10–14. https://doi.org/10.1016/j.jns.2008.05.023Hong YH, Kwon SB, Kim BJ, Kim BJ, Kim SH, Kim JK et al. Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients. J Neurol Sci. 2008;273(1–2):10–14. https://doi.org/10.1016/j.jns.2008.05.023Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study [published correction appears in Am J Ophthalmol. 2020 Jul 3;]. Am J Ophthalmol. 2019;205:99–105. https://doi.org/10.1016/j.ajo.2019.04.01755. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570–2581. https://doi.org/10.1056/NEJMra1602678Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, Epidemiology, and Transformation of Ocular Myasthenia Gravis: A Population-Based Study [published correction appears in Am J Ophthalmol. 2020 Jul 3;]. Am J Ophthalmol. 2019;205:99–105. https://doi.org/10.1016/j.ajo.2019.04.01755. Gilhus NE. Myasthenia Gravis. N Engl J Med. 2016;375(26):2570–2581. https://doi.org/10.1056/NEJMra1602678Sih M, Soliven B, Mathenia N, Jacobsen J, Rezania K. Headdrop: A frequent feature of late-onset myasthenia gravis. Muscle Nerve. 2017;56(3):441–444. https://doi.org/10.1002/mus.25526Sih M, Soliven B, Mathenia N, Jacobsen J, Rezania K. Headdrop: A frequent feature of late-onset myasthenia gravis. Muscle Nerve. 2017;56(3):441–444. https://doi.org/10.1002/mus.25526Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic Syndromes. Continuum (Minneap Minn). 2019;25(6):1767–1784. https://doi.org/10.1212/CON.0000000000000800Ciafaloni E. Myasthenia Gravis and Congenital Myasthenic Syndromes. Continuum (Minneap Minn). 2019;25(6):1767–1784. https://doi.org/10.1212/CON.0000000000000800Grob D. Course and management of myasthenia gravis. J Am Med Assoc. 1953;153(6):529–532. https://doi.org/10.1001/jama.1953.02940230001001Grob D. Course and management of myasthenia gravis. J Am Med Assoc. 1953;153(6):529–532. https://doi.org/10.1001/jama.1953.02940230001001Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978–1980. https://doi.org/10.1212/01.wnl.0000065882.63904.53Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978–1980. https://doi.org/10.1212/01.wnl.0000065882.63904.53Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, Herbelin L et al. Clinical fi ndings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010;41(3):370–374. https://doi.org/10.1002/mus.21533Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, Herbelin L et al. Clinical fi ndings in MuSK-antibody positive myasthenia gravis: a U.S. experience. Muscle Nerve. 2010;41(3):370–374. https://doi.org/10.1002/mus.21533Rivner MH, Liu S, Quarles B, Fleenor B, Shen C, Pan J, Mei L. Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve. 2017;55(3):430–432. https://doi.org/10.1002/mus.25438Rivner MH, Liu S, Quarles B, Fleenor B, Shen C, Pan J, Mei L. Agrin and low-density lipoprotein-related receptor protein 4 antibodies in amyotrophic lateral sclerosis patients. Muscle Nerve. 2017;55(3):430–432. https://doi.org/10.1002/mus.25438Tzartos JS, Zisimopoulou P, Rentzos M, Karandreas N, Zouvelou V, Evangelakou P et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014;1(2):80–87. https://doi.org/10.1002/acn3.26Tzartos JS, Zisimopoulou P, Rentzos M, Karandreas N, Zouvelou V, Evangelakou P et al. LRP4 antibodies in serum and CSF from amyotrophic lateral sclerosis patients. Ann Clin Transl Neurol. 2014;1(2):80–87. https://doi.org/10.1002/acn3.26Weksler B, Lu B. Alterations of the immune system in thymic malignancies. J Thorac Oncol. 2014;9(9Suppl2):S137–S142. https://doi.org/10.1097/JTO.0000000000000299Weksler B, Lu B. Alterations of the immune system in thymic malignancies. J Thorac Oncol. 2014;9(9Suppl2):S137–S142. https://doi.org/10.1097/JTO.0000000000000299Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176–188. https://doi.org/10.1016/S1474-4422(21)00297-0Punga AR, Maddison P, Heckmann JM, Guptill JT, Evoli A. Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022;21(2):176–188. https://doi.org/10.1016/S1474-4422(21)00297-0Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419–425. https://doi.org/10.1212/WNL.0000000000002790Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology. 2016;87(4):419–425. https://doi.org/10.1212/WNL.0000000000002790Detterbeck F, French CA, Hornick JL, Inagaki H, Jain D, Lazar AJ et al. The 2021 WHO Classifi cation of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? J Thorac Oncol. 2022;17(2):200–213. https://doi.org/10.1016/j.jtho.2021.10.010Detterbeck F, French CA, Hornick JL, Inagaki H, Jain D, Lazar AJ et al. The 2021 WHO Classifi cation of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors? J Thorac Oncol. 2022;17(2):200–213. https://doi.org/10.1016/j.jtho.2021.10.010Lefeuvre CM, Payet CA, Fayet OM, Maillard S, Truff ault F, Bondet V et al. Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers. J Autoimmun. 2020;106:102337. https://doi.org/10.1016/j.jaut.2019.102337Lefeuvre CM, Payet CA, Fayet OM, Maillard S, Truff ault F, Bondet V et al. Risk factors associated with myasthenia gravis in thymoma patients: The potential role of thymic germinal centers. J Autoimmun. 2020;106:102337. https://doi.org/10.1016/j.jaut.2019.102337Yamada Y, Yoshida S, Iwata T, Suzuki H, Tagawa T, Mizobuchi T et al. Risk factors for developing postthymectomy myasthenia gravis in thymoma patients. Ann Thorac Surg. 2015;99(3):1013–1019. https://doi.org/10.1016/j.athoracsur.2014.10.068Yamada Y, Yoshida S, Iwata T, Suzuki H, Tagawa T, Mizobuchi T et al. Risk factors for developing postthymectomy myasthenia gravis in thymoma patients. Ann Thorac Surg. 2015;99(3):1013–1019. https://doi.org/10.1016/j.athoracsur.2014.10.068Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114–122. https://doi.org/10.1212/WNL.0000000000011124Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114–122. https://doi.org/10.1212/WNL.0000000000011124Ye B, Tantai JC, Ge XX, Li W, Feng J, Cheng M et al. Surgical techniques for early-stage thymoma: video-assisted thoracoscopic thymectomy versus transsternal thymectomy. J Thorac Cardiovasc Surg. 2014;147(5):1599–1603. https://doi.org/10.1016/j.jtcvs.2013.10.053Ye B, Tantai JC, Ge XX, Li W, Feng J, Cheng M et al. Surgical techniques for early-stage thymoma: video-assisted thoracoscopic thymectomy versus transsternal thymectomy. J Thorac Cardiovasc Surg. 2014;147(5):1599–1603. https://doi.org/10.1016/j.jtcvs.2013.10.053Xi J, Wang L, Yan C, Song J, Song Y, Chen J et al. The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells. J Thorac Dis. 2019;11(6):2315–2323. https://doi.org/10.21037/jtd.2019.06.01Xi J, Wang L, Yan C, Song J, Song Y, Chen J et al. The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells. J Thorac Dis. 2019;11(6):2315–2323. https://doi.org/10.21037/jtd.2019.06.01De Rosa A, Fornili M, Maestri Tassoni M, Guida M, Baglietto L, Petrucci L et al. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thorac Cancer. 2021;12(1):106–113. https://doi.org/10.1111/1759-7714.13724De Rosa A, Fornili M, Maestri Tassoni M, Guida M, Baglietto L, Petrucci L et al. Thymoma-associated myasthenia gravis: Clinical features and predictive value of antiacetylcholine receptor antibodies in the risk of recurrence of thymoma. Thorac Cancer. 2021;12(1):106–113. https://doi.org/10.1111/1759-7714.13724Szczudlik P, Szyluk B, Lipowska M, Ryniewicz B, Kubiszewska J, Dutkiewicz M et al. Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand. 2014;130(4):229–233. https://doi.org/10.1111/ane.12271Szczudlik P, Szyluk B, Lipowska M, Ryniewicz B, Kubiszewska J, Dutkiewicz M et al. Antititin antibody in early- and late-onset myasthenia gravis. Acta Neurol Scand. 2014;130(4):229–233. https://doi.org/10.1111/ane.12271Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 2001;57(9):1579–1582. https://doi.org/10.1212/wnl.57.9.1579Buckley C, Newsom-Davis J, Willcox N, Vincent A. Do titin and cytokine antibodies in MG patients predict thymoma or thymoma recurrence? Neurology. 2001;57(9):1579–1582. https://doi.org/10.1212/wnl.57.9.1579Gastaldi M, De Rosa A, Maestri M, Zardini E, Scaranzin S, Guida M et al. Acquired neuromyotonia in thymoma-associated myasthenia gravis: a clinical and serological study. Eur J Neurol. 2019;26(7):992–999. https://doi.org/10.1111/ene.13922Gastaldi M, De Rosa A, Maestri M, Zardini E, Scaranzin S, Guida M et al. Acquired neuromyotonia in thymoma-associated myasthenia gravis: a clinical and serological study. Eur J Neurol. 2019;26(7):992–999. https://doi.org/10.1111/ene.13922Masuda T, Motomura M, Utsugisawa K, Nagane Y, Nakata R, Tokuda M et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2012;83(9):935–940. https://doi.org/10.1136/jnnp-2012-302705Masuda T, Motomura M, Utsugisawa K, Nagane Y, Nakata R, Tokuda M et al. Antibodies against the main immunogenic region of the acetylcholine receptor correlate with disease severity in myasthenia gravis. J Neurol Neurosurg Psychiatry. 2012;83(9):935–940. https://doi.org/10.1136/jnnp-2012-302705Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113–124. https://doi.org/10.1038/s41582-018-0110-zDalakas MC. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol. 2019;15(2):113–124. https://doi.org/10.1038/s41582-018-0110-zПикин ОВ, Рябов АБ, Щербакова НИ, Глушко ВА, Колбанов КИ, Бармин ВВ и др. Ретимэктомия у больных миастенией и рецидивом опухоли вилочковой железы. Хирургия. Журнал им. Н.И. Пирогова. 2021;9:27–33. https://doi.org/10.17116/hirurgia202109127Pikin OV, Ryabov AB, Shcherbakova NI, Glushko VA, Kolbanov KI, Barmin VV et al. Rethymectomy in patients with myasthenia gravis and recurrent thymoma. Pirogov Russian Journal of Surgery (Khirurgiya. Zurnal im. N.I. Pirogova). 2021;9:27–33. (In Russ.). https://doi.org/10.17116/hirurgia202109127Шевченко ЮЛ, Ветшев ПС, Санадзе АГ, Аблицов АЮ, Сиднев ДВ, Дедаев СИ, Магомедов Б. Антитела к ацетилхолиновому рецептору в оценке эффективности тимэктомии у больных с генерализованной миастенией. Вестник Национального медико-хирургического центра им. Н.И. Пирогова. 2011;6(4):15–19.Shevchenko YL, Vetshev PS, Sanadze AG, Ablitsov AYu, Sidnev DV, Dedaev SI, Magomedov B. Antibodies to the acetylcholine receptor in assessing the eff ectiveness of thymectomy in patients with generalized myasthenia gravis. Bulletin of the National Medical and Surgical Center named after N.I. Pirogov (Vestnik Nacionalnogo mediko-hirurgicheskogo Centra im. N.I. Pirogova). 2011;6(4):15–19. (In Russ.).Санадзе АГ. Критерии диагностики миастении. Болезни нервной системы: механизмы развития, диагностика и лечение. 2017:107–131.Sanadze AG. Criteria for the diagnosis of myasthenia gravis. Diseases of the nervous system: mechanisms of development, diagnosis and treatment (Bolezni nervnoj sistemy: mekhanizmy razvitiya, diagnostika i lechenie). 2017:107–131. (In Russ.).Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311–337. https://doi.org/10.1016/j.ncl.2018.01.011Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol Clin. 2018;36(2):311–337. https://doi.org/10.1016/j.ncl.2018.01.011Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas- García R, Suárez-Calvet X et al. Long-lasting treatment eff ect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189–193. https://doi.org/10.1212/WNL.0b013e3182407982Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas- García R, Suárez-Calvet X et al. Long-lasting treatment eff ect of rituximab in MuSK myasthenia. Neurology. 2012;78(3):189–193. https://doi.org/10.1212/WNL.0b013e3182407982Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(4):392–395. https://doi.org/10.1136/jnnp-2019-322606Di Stefano V, Lupica A, Rispoli MG, Di Muzio A, Brighina F, Rodolico C. Rituximab in AChR subtype of myasthenia gravis: systematic review. J Neurol Neurosurg Psychiatry. 2020;91(4):392–395. https://doi.org/10.1136/jnnp-2019-322606Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006;33(4):575–580. https://doi.org/10.1002/mus.20479Hain B, Jordan K, Deschauer M, Zierz S. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve. 2006;33(4):575–580. https://doi.org/10.1002/mus.20479Щербакова НИ, Супонева НА, Шведков ВВ, Шабалина АА, Костырева МВ, Рудниченко ВА, Галкина ОИ. Российский опыт успешного применения ритуксимаба при рефрактерных формах миастении гравис. Нервно-мышечные болезни. 2015;5(3):50–61. https://doi.org/10.17650/2222-8721-2015-5-3-50-61Shcherbakova NI, Suponeva NA, Shvedkov VV, Shabalina AA, Kostyreva MV, Rudnichenko VA, Galkina OI. Russian experience of successful use of rituximab in refractory forms of myasthenia gravis. Neuromuscular diseases (Nervno-myshechnye bolezni). 2015;5(3):50–61. (In Russ.). https://doi.org/10.17650/2222-8721-2015-5-3-50-61

The authors declare that there are no conflicts of interest present.